טוען...
Grb2-SH3 ligand inhibits the growth of HER2(+) cancer cells and has antitumor effects in human cancer xenografts alone and in combination with docetaxel
HER2 represents an important signaling pathway in breast and other cancers. Herceptin has demonstrated clinical activity, but resistance is common. Thus, new therapeutic approaches to the HER2 pathway are needed. Grb2 is an adaptor protein involved in Ras-dependent signaling induced by HER2 receptor...
שמור ב:
| Main Authors: | , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Wiley-Liss
2007
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2755772/ https://ncbi.nlm.nih.gov/pubmed/17372910 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.22674 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|